Publication

The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases

van der Werf, L. R., Wassenaar, E., de Niet, A., Lalezari, F., Braam, H. J., van Ramshorst, B., Nederend, J., de Hingh, I. H. J. T., Kok, N. F. M. & Aalbers, A. G. J., Mar-2019, In : European Journal of Surgical Oncology. 45, 3, p. 376-382 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

van der Werf, L. R., Wassenaar, E., de Niet, A., Lalezari, F., Braam, H. J., van Ramshorst, B., ... Aalbers, A. G. J. (2019). The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases. European Journal of Surgical Oncology, 45(3), 376-382. https://doi.org/10.1016/j.ejso.2018.10.540

Author

van der Werf, L R ; Wassenaar, E ; de Niet, A ; Lalezari, F ; Braam, H J ; van Ramshorst, B ; Nederend, J ; de Hingh, I H J T ; Kok, N F M ; Aalbers, A G J. / The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases. In: European Journal of Surgical Oncology. 2019 ; Vol. 45, No. 3. pp. 376-382.

Harvard

van der Werf, LR, Wassenaar, E, de Niet, A, Lalezari, F, Braam, HJ, van Ramshorst, B, Nederend, J, de Hingh, IHJT, Kok, NFM & Aalbers, AGJ 2019, 'The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases', European Journal of Surgical Oncology, vol. 45, no. 3, pp. 376-382. https://doi.org/10.1016/j.ejso.2018.10.540

Standard

The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases. / van der Werf, L R; Wassenaar, E; de Niet, A; Lalezari, F; Braam, H J; van Ramshorst, B; Nederend, J; de Hingh, I H J T; Kok, N F M; Aalbers, A G J.

In: European Journal of Surgical Oncology, Vol. 45, No. 3, 03.2019, p. 376-382.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

van der Werf LR, Wassenaar E, de Niet A, Lalezari F, Braam HJ, van Ramshorst B et al. The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases. European Journal of Surgical Oncology. 2019 Mar;45(3):376-382. https://doi.org/10.1016/j.ejso.2018.10.540


BibTeX

@article{8fef578b39c8451aace8f6424683b579,
title = "The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases",
abstract = "OBJECTIVES: To investigate the impact of retroperitoneal lymphadenopathy (RPLP) on pre-operative CT scan on overall survival (OS) and disease-free survival (DFS) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for peritoneal metastases (PM) of colorectal cancer.BACKGROUND: In patients with PM enlarged retroperitoneal lymph nodes (RPLP) are usually considered extra-regional lymph node metastases and therefore these patients may be excluded from CRS-HIPEC. This is a clinical dilemma since it is often hard to obtain histology from these nodes.METHODS: In this multicenter, retrospective study all consecutive patients with colorectal PM treated with CRS-HIPEC between 2004 and 2013 were included. The preoperative CT-scan was re-analyzed for the presence of RPLP based on the radiological appearance of enlarged lymph nodes. Outcomes were OS and DFS. Kaplan-Meier methods and Cox regression modeling were used to analyze the impact of RPLP on OS and DFS.RESULTS: In 25 of 401 patients (6.1{\%}) RPLP was observed on the preoperative CT-scan. Patient, tumor and surgical characteristics did not statistically significantly differ between groups with and without RPLP. After a median follow-up of 46 months, the one-, three- and five-year survival was 80{\%}, 59{\%}, 38{\%} and 90{\%}, 50{\%}, 36{\%} in the group with and without RPLP respectively. Median OS (47 vs. 35 months, logrank: p = 0.70) and median DFS (14 vs. 15 months, logrank: p = 0.81) did not statistically significantly differ between groups. In multivariable analysis, RPLP did not significantly influence survival.CONCLUSION: Enlarged retroperitoneal lymph nodes on a pre-operative CT-scan should not automatically exclude patients from CRS-HIPEC.",
keywords = "Aged, Colorectal Neoplasms/mortality, Cytoreduction Surgical Procedures/methods, Disease-Free Survival, Female, Follow-Up Studies, Humans, Hyperthermia, Induced/methods, Lymph Nodes/diagnostic imaging, Lymphadenopathy/diagnosis, Male, Middle Aged, Netherlands/epidemiology, Peritoneal Neoplasms/diagnosis, Retrospective Studies, Survival Rate/trends, Time Factors, Tomography, X-Ray Computed/methods",
author = "{van der Werf}, {L R} and E Wassenaar and {de Niet}, A and F Lalezari and Braam, {H J} and {van Ramshorst}, B and J Nederend and {de Hingh}, {I H J T} and Kok, {N F M} and Aalbers, {A G J}",
note = "Copyright {\circledC} 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.",
year = "2019",
month = "3",
doi = "10.1016/j.ejso.2018.10.540",
language = "English",
volume = "45",
pages = "376--382",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "ELSEVIER SCI LTD",
number = "3",

}

RIS

TY - JOUR

T1 - The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases

AU - van der Werf, L R

AU - Wassenaar, E

AU - de Niet, A

AU - Lalezari, F

AU - Braam, H J

AU - van Ramshorst, B

AU - Nederend, J

AU - de Hingh, I H J T

AU - Kok, N F M

AU - Aalbers, A G J

N1 - Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

PY - 2019/3

Y1 - 2019/3

N2 - OBJECTIVES: To investigate the impact of retroperitoneal lymphadenopathy (RPLP) on pre-operative CT scan on overall survival (OS) and disease-free survival (DFS) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for peritoneal metastases (PM) of colorectal cancer.BACKGROUND: In patients with PM enlarged retroperitoneal lymph nodes (RPLP) are usually considered extra-regional lymph node metastases and therefore these patients may be excluded from CRS-HIPEC. This is a clinical dilemma since it is often hard to obtain histology from these nodes.METHODS: In this multicenter, retrospective study all consecutive patients with colorectal PM treated with CRS-HIPEC between 2004 and 2013 were included. The preoperative CT-scan was re-analyzed for the presence of RPLP based on the radiological appearance of enlarged lymph nodes. Outcomes were OS and DFS. Kaplan-Meier methods and Cox regression modeling were used to analyze the impact of RPLP on OS and DFS.RESULTS: In 25 of 401 patients (6.1%) RPLP was observed on the preoperative CT-scan. Patient, tumor and surgical characteristics did not statistically significantly differ between groups with and without RPLP. After a median follow-up of 46 months, the one-, three- and five-year survival was 80%, 59%, 38% and 90%, 50%, 36% in the group with and without RPLP respectively. Median OS (47 vs. 35 months, logrank: p = 0.70) and median DFS (14 vs. 15 months, logrank: p = 0.81) did not statistically significantly differ between groups. In multivariable analysis, RPLP did not significantly influence survival.CONCLUSION: Enlarged retroperitoneal lymph nodes on a pre-operative CT-scan should not automatically exclude patients from CRS-HIPEC.

AB - OBJECTIVES: To investigate the impact of retroperitoneal lymphadenopathy (RPLP) on pre-operative CT scan on overall survival (OS) and disease-free survival (DFS) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for peritoneal metastases (PM) of colorectal cancer.BACKGROUND: In patients with PM enlarged retroperitoneal lymph nodes (RPLP) are usually considered extra-regional lymph node metastases and therefore these patients may be excluded from CRS-HIPEC. This is a clinical dilemma since it is often hard to obtain histology from these nodes.METHODS: In this multicenter, retrospective study all consecutive patients with colorectal PM treated with CRS-HIPEC between 2004 and 2013 were included. The preoperative CT-scan was re-analyzed for the presence of RPLP based on the radiological appearance of enlarged lymph nodes. Outcomes were OS and DFS. Kaplan-Meier methods and Cox regression modeling were used to analyze the impact of RPLP on OS and DFS.RESULTS: In 25 of 401 patients (6.1%) RPLP was observed on the preoperative CT-scan. Patient, tumor and surgical characteristics did not statistically significantly differ between groups with and without RPLP. After a median follow-up of 46 months, the one-, three- and five-year survival was 80%, 59%, 38% and 90%, 50%, 36% in the group with and without RPLP respectively. Median OS (47 vs. 35 months, logrank: p = 0.70) and median DFS (14 vs. 15 months, logrank: p = 0.81) did not statistically significantly differ between groups. In multivariable analysis, RPLP did not significantly influence survival.CONCLUSION: Enlarged retroperitoneal lymph nodes on a pre-operative CT-scan should not automatically exclude patients from CRS-HIPEC.

KW - Aged

KW - Colorectal Neoplasms/mortality

KW - Cytoreduction Surgical Procedures/methods

KW - Disease-Free Survival

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Hyperthermia, Induced/methods

KW - Lymph Nodes/diagnostic imaging

KW - Lymphadenopathy/diagnosis

KW - Male

KW - Middle Aged

KW - Netherlands/epidemiology

KW - Peritoneal Neoplasms/diagnosis

KW - Retrospective Studies

KW - Survival Rate/trends

KW - Time Factors

KW - Tomography, X-Ray Computed/methods

U2 - 10.1016/j.ejso.2018.10.540

DO - 10.1016/j.ejso.2018.10.540

M3 - Article

VL - 45

SP - 376

EP - 382

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 3

ER -

ID: 92268074